Kwality Pharmaceuticals Q1FY27: Revenue up 46%, PAT doubles

Strong start to FY27 on execution and regulatory footprint

Kwality Pharmaceuticals reported a robust opening quarter for FY27, with sharp year-on-year improvement in both revenue and profitability. The company attributed the performance to strong execution, improved margins, and an expanding regulatory footprint. For investors, the key takeaway was not just the quarter’s growth but also management’s decision to raise full-year guidance for FY27. That combination signals confidence in sustaining momentum beyond a single quarter.

The results cover the quarter ended June 30, 2026. Along with the quarterly update, the company’s broader FY25-26 (FY26) standalone numbers were also highlighted, including margin expansion and working capital improvement. Separately, the company’s 43rd Annual General Meeting (AGM) has been scheduled for August 31, 2026, via video conferencing and other audio-visual means.

Q1FY27 revenue jumps to ₹162 crore

In Q1FY27, consolidated revenue rose 46% year-on-year to ₹162 crore, up from ₹112 crore in Q1FY26. The scale-up indicates a materially higher run-rate versus the year-ago quarter. The update described the growth as being driven by strong execution and a widening regulatory footprint, which typically supports access to more markets and product registrations.

Revenue growth mattered because it came alongside margin improvement, not at the cost of profitability. That helped translate top-line expansion into a disproportionately higher increase in net profit. The quarter, therefore, stands out for the degree of operating leverage visible in the reported metrics.

Profitability improves, supported by margin expansion

EBITDA for Q1FY27 increased 13% to ₹41 crore from ₹37 crore in Q1FY26. The EBITDA margin expanded to 25.3% from 21.9%, a 340 basis point improvement. This indicates that the revenue growth was accompanied by better operating efficiency and cost control during the period.

Net profit after tax (PAT) more than doubled, increasing 119% year-on-year to ₹26 crore from ₹12 crore. PAT margin rose to 16% from 11%, expanding by 500 basis points. The margin movement, as presented in the update, was a central driver behind the sharp rise in bottom-line results.

Key Q1FY27 numbers at a glance

FY27 guidance raised for revenue, EBITDA and PAT

Following the quarter, management raised full-year guidance for FY27 across revenue, EBITDA, and PAT. The company is now targeting revenue of over ₹700 crore for FY27, described as implying year-on-year growth of over 39%. For profitability, it guided to EBITDA of ₹189–196 crore or more, implying an EBITDA margin of 27–28% or higher.

On the bottom line, the company guided to PAT of at least ₹109 crore, corresponding to a net profit margin of approximately 15.5% or higher. The guidance revision was positioned as reflecting confidence in sustained growth momentum, supported by margin improvement and regulatory milestones.

FY25-26 standalone performance: revenue at ₹503.06 crore

In the FY25-26 period, the company reported standalone revenue from operations of ₹503.06 crore, up 35.89% from ₹370.20 crore in FY24-25. Standalone PAT rose 68.83% to ₹67.35 crore, compared with ₹39.89 crore in the previous fiscal year. These figures were presented as part of the annual financial outcome and provide context to the higher FY27 revenue ambition.

The update also noted that the EBITDA margin expanded by around 200 basis points to approximately 24% for FY25-26. Alongside profitability, working capital efficiency improved as the cash conversion cycle was reported at 170 days, improving from 208 days.

Long-term target: over ₹1,000 crore revenue by FY29

Beyond FY27, the company also stated a longer-term goal of achieving revenue of over ₹1,000 crore by FY29. The narrative around this target referenced an expanded product mix and a focus on international markets. While the update did not provide a detailed bridge or segment-wise breakup, it framed the target as part of a multi-year growth plan anchored in key therapeutic areas and market expansion.

For readers tracking execution, the FY29 milestone is important because it creates an external benchmark against which subsequent quarterly run-rates and regulatory progress can be evaluated.

Additional quarterly and trailing financial data points shared

The material also included a quarterly data set (in ₹ crore) showing net sales across Mar 2025 to Mar 2026, with net sales of 115.68 (Mar 2025), 111.48 (Jun 2025), 111.31 (Sep 2025), 123.45 (Dec 2025), and 156.82 (Mar 2026). Over the same periods, operating profit was listed as 25.9, 24.19, 25.35, 29.95, and 38.74.

Separately, a line item noted “Total Revenue for Q4FY26” as ₹158.17 crore (converted from ₹15,817.17 lakh), with QoQ growth of 27.59% and YoY growth of 35.84%. Another snapshot cited Q4 FY25-26 (dated May 19, 2026) revenue of ₹157 crore and net profit of ₹25 crore.

AGM date and what shareholders should note

Kwality Pharmaceuticals’ 43rd AGM is scheduled for Monday, August 31, 2026 at 12:00 noon, to be held through video conferencing or other audio visual means. For shareholders, AGM communication is typically where companies outline resolutions, provide operational commentary, and address questions on strategy and performance.

The update did not list agenda items, but the timing places the AGM after the company has reported the strong Q1FY27 performance and raised guidance, which may shape shareholder focus during discussions.

Market snapshots cited: share price references

The content included two separate share price references: one stating a current share price of ₹2,611.8, and another citing CMP (current market price) of ₹2,591. Because both figures were presented, readers should treat them as snapshots from different points in time rather than a single definitive quote.

A separate note also listed a 12-month target range of ₹3,109 to ₹3,446 (Uniresearch estimate) alongside Q1FY27 estimate ranges, but the company has already reported actual Q1FY27 numbers in the same material.

Why the quarter matters: operating leverage and guidance credibility

The key analytical point from the reported numbers is the combination of high revenue growth and a meaningful rise in margins. While EBITDA rose 13%, PAT rose 119%, supported by the improvement in PAT margin to 16% from 11%. Such a spread between EBITDA growth and PAT growth, as presented, underscores how margin expansion and operating leverage can accelerate bottom-line performance.

The raised FY27 guidance provides a clear set of measurable targets: revenue over ₹700 crore, EBITDA ₹189–196 crore or more, and PAT at least ₹109 crore. Over the coming quarters, the market is likely to compare quarterly revenue run-rates and margin trends against these targets, especially given the explicit margin expectations embedded in the EBITDA guidance.

Conclusion

Kwality Pharmaceuticals’ Q1FY27 results showed strong year-on-year growth, with revenue at ₹162 crore and PAT at ₹26 crore, alongside improved EBITDA and margin expansion. Management has raised FY27 guidance for revenue, EBITDA and PAT, and reiterated longer-term revenue ambitions through FY29. The next formal milestone for shareholders is the AGM on August 31, 2026, following the company’s strong start to the fiscal year.